Update on the diagnosis and treatment of human papillomavirus infection

Cleveland Clinic Journal of Medicine

Volumn 69, Issue 12, 2002, Pages 948-961

  Zanotti, Kristine M ^a   Belinson, Jerome ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERFERON; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON; UNCLASSIFIED DRUG; VERRUCA VACCINE; VIRUS DNA; VIRUS VACCINE;

CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COCARCINOGENESIS; COLPOSCOPY; CONDYLOMA; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FLU LIKE SYNDROME; GENITAL TRACT CANCER; HUMAN; IMMUNE STATUS; INFLAMMATION; LEUKOPENIA; NONHUMAN; PAPANICOLAOU TEST; REVIEW; SEXUALLY TRANSMITTED DISEASE; STRAIN DIFFERENCE; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS; VIRUS DETECTION; VIRUS TRANSMISSION; VIRUS VIRULENCE; WART VIRUS;

EID: 0036922894     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.12.948     Document Type: Review

References (33)

1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87:796-802.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
3. Koutsky L. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus. N Engl J Med 1992; 327:1272-1278.
4. Dillner J, von Krogh G, Horenblas S, et al. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol 2000; 205(suppl):189-193.
5. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3-8.
6. Oriel JD. Natural history of genital warts. Br J Vener Dis 1971; 47:1-13.
7. De Villiers EM, Wagner D, Schneider A, et al. Human papillomavirus DNA in women without and with cytological abnormalities: results of a 5-year follow-up study. Gynecol Oncol 1992; 44:33-39.
8. Moscicki AB, Palefsky J, Smith G, et al. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstet Gynecol 1993; 82:578-585.
9. Chua KL, Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996; 77:121-127.
10. Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999; 341:1633-1638.
11. Nobbenhuis MAE, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening: a prospective study. Lancet 1999; 354:20-25.
12. Ries LAG, Kosary CL, Hankey BF, Miller BA, Edwards BK, editors. SEER Cancer Statistics Review, 1973-1995. Bethesda, Md: National Cancer Institute, 1998.
13. Solomon D, Schiffman M, Tarone R. For the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93:293-299.
14. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000; 92:397-402.
15. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. JAMA 1994; 271:1866-1869.
16. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001; 83:439-444.
17. Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999; 281:1605-1610.
18. Cuzick J. Human papillomavirus testing for primary cervical cancer screening. JAMA 2000; 283:108-109.
19. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992; 79:328-337.
20. Schiffman MH. Latest HPV findings: some clinical implications. Contemp Ob Gyn 1993; 27-41.
21. Melkert PW, Hopman E, van den Brule AJ, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993; 53:919-923.
22. Frisch M, Friis S, Kjaer SK, Melbye M. Failing incidence of penis cancer in an uncircumcised population. BMJ 1995; 311:1471.
23. Cummings B, Keane T, Thomas G, et al. Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy. Cancer 1984, 54:2062-2068.
24. Gollnick H, Barasso R, Jappe U, et al. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS 2001; 12:22-28.
25. Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998; 42:789-794,
26. Davis G, Wentworth J, Richard J. Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia. A report of four cases. J Reprod Med 2000; 45:619-623.
27. Pehoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol 2001; 137:14-16.
28. Kerby PK, Kiviat N, Beckman A, Wells D, Sherwin S, Corey L. Tolerance and efficacy of recombinant human interferon-gamma in the treatment of refractory genital warts. Am J Med 1988; 85:183-188.
29. Schonfeld A, Nitke S, Schattner A, et al. Intramuscular human interferon-beta injections in treatment of condylomata acuminata. Lancet 1984; 1:1038-1042.
30. Kraus SJ, Stone KM. Management of genital infection caused by human papillomavirus. Rev Infect Dis 1990; 12(suppl 6):620-632.
31. Ferenczy A, Mitao M, Nagai N, et al. Latent papillomavirus and recurring genital warts. N Engl J Med 1985; 313:784-788.
32. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336:1855-1859.
33. Murakami M. Gurski KJ, Stellar MJ. Human papillomavirus vaccines for cervical cancer. J Immunother 1999; 22:212-218.